Biocon rolls out two biosimilars in US market

Biocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They are now available through specialty pharmacies and healthcare providers. The US Food and Drug Administration previously approved them. This launch expands Biocon's portfolio and aims to provide affordable treatment options for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CptEBOD
via IFTTT